Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With Cancer: A Retrospective Analysis.
Aged
Antiemetics
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Aprepitant
/ administration & dosage
Female
Humans
Infusions, Intravenous
Male
Nausea
/ chemically induced
Neoplasms
/ complications
Neurokinin-1 Receptor Antagonists
/ administration & dosage
Retrospective Studies
Vomiting
/ chemically induced
Journal
Journal of infusion nursing : the official publication of the Infusion Nurses Society
ISSN: 1539-0667
Titre abrégé: J Infus Nurs
Pays: United States
ID NLM: 101124170
Informations de publication
Date de publication:
Historique:
entrez:
30
8
2019
pubmed:
30
8
2019
medline:
1
1
2020
Statut:
ppublish
Résumé
HTX-019 is a neurokinin 1 receptor antagonist approved for prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients with cancer receiving moderately and highly emetogenic chemotherapy. When administered as a 30-minute intravenous (IV) infusion, HTX-019 has displayed a tolerable and favorable safety profile in healthy subjects. This is the first study to evaluate the safety profile of multiple HTX-019 infusions in patients with cancer. This retrospective analysis shows that HTX-019 administered via IV infusion has a favorable safety profile in patients with cancer, and no new treatment-emergent adverse events were identified.
Identifiants
pubmed: 31464835
doi: 10.1097/NAN.0000000000000341
pii: 00129804-201909000-00007
pmc: PMC7328855
doi:
Substances chimiques
Antiemetics
0
Neurokinin-1 Receptor Antagonists
0
Aprepitant
1NF15YR6UY
Types de publication
Journal Article
Langues
eng
Pagination
260-263Références
Drug Des Devel Ther. 2018 Mar 01;12:429-435
pubmed: 29535504
J Clin Oncol. 2017 Oct 1;35(28):3240-3261
pubmed: 28759346
Support Care Cancer. 2017 Jan;25(1):277-288
pubmed: 27443154
Support Care Cancer. 2017 Jan;25(1):289-294
pubmed: 27510316
Future Oncol. 2018 Nov;14(27):2849-2859
pubmed: 29873529